Patients Dosed in R327 Diabetic Foot Infection Trial

® ® ® efficacy of RECCE 327 (R327) as a topical broad-spectrum, dosed daily over 14 days as a potential topical anti-infective treatment for patients with mild skin and soft tissue diabetic Each year the High-Risk Foot Service (HRFS) at Liverpool Hospital manages approximately 800 patients presenting with complex foot disease, with over 80% occurring in people with diabetes. The study is supported